Treatment of bone diseases

Details Treatment of bone diseases Treatment of bone diseases

2006-07-18

2006-07-18

Pak, John (Department: 1616)

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Heavy metal or compound thereof

C424S600000, C424S667000, C424S673000, C424S676000, C424S677000, C424S682000, C424S702000, C424S715000, C424S722000, C424SDIG006, C514S002600, C514S012200, C514S102000, C514S107000, C514S108000, C514S114000, C514S167000, C514S168000, C514S169000, C514S170000, C514S171000, C514S182000, C514S184000, C514S185000, C514S186000, C514S187000, C514S188000, C514S324000, C514S460000, C514S492000, C514S533000, C514S648000, C514S825000, C514S836000, C514S900000

Reexamination Certificate

active

07078059

ABSTRACT:
The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.

REFERENCES:
patent: 5342604 (1994-08-01), Wilson et al.
patent: 5714631 (1998-02-01), Wilson et al.
patent: 5902825 (1999-05-01), Jia
patent: 5968976 (1999-10-01), Murrer et al.
patent: 6027737 (2000-02-01), Morris, Jr. et al.
patent: 2004/0082588 (2004-04-01), Evans et al.
patent: 2005/0079135 (2005-04-01), Haslam et al.
patent: 2 493 704 (1980-11-01), None
patent: WO 96/30029 (1996-10-01), None
DRUGU abstract, accession No. 1987-06492; abstracting Singh et al., Curr. Sci., vol. 55, No. 17, pp. 846-848 (1986).
‘Renal Osteodystrophy’. National Institute of Diabetes and Digestive and Kidney Diseases [online]. Posted May 2001 [retrieve on Jan. 24, 2003]. Retrieved from the Internet: <URL: www.niddk.nih.gov/healthykidney/pus/kidney-failure/renal- osteodystrophy.htm.
Fernandez-Gavarron et al., “Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite”,Bone and Mineral 3, 1998, pp. 283-291.
Yanagihara et al., “Synthesis of Lanthanide Carbonates”,Journal of the Less-Common Metals, 167: 1991, pp 223-232.
Guggino et al., “Bone remodeling signaled by a dihydropyridine- and phenylalkylamine-sensitive calcium channel”,Proc. Natl. Acad. Sci., 86:Apr. 1999, pp. 2957-2960.
Graff et al., “A Possible Non-aluminum oral phosphate binder? A Comparative Study on Dietary Phosphorus Absorption”,Research Communications in Molecular Pathology and Pharmacology, Sep. 1995, pp, 373-388, vol. 89, No. 3.
Hergesell et al., Phosphate binders on iron basis: A new perspective?,Kidney International, 1999, pp. S-42-S-45, vol. 56., Suppl. 73.
Hutchison et al., “Calcitrol, Lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy”,Procedings of the ISPD '98—The VIIIth Congress of the ISPD, Aug. 28-26, 1998, pp. S408-S412.
J. McClure et al., “The production of Calcification in connective Tissue and Skeletal Muscle Using Various Chemical Compounds”,Calicif Tiss. Res., 22: 1976, pp. 129-135.
Shankar et al., Activation and inactivation of the osteoclast Ca2+receptor by the trivalent cation, La3+,Biochemicaland Biophysical Research Communications, 187 (2): Sep. 16, 1992, pp 907-912.
Zimmermann et al., “Inhibition of chondrogenesis and endochrondral mineralization in vitro by different calcium channel blockers”,European Journal of Cell Biology, 1994, pp. 114-121, vol. 63.
Harris et al., “The Effect of Lanthanum Chloride and related Compounds on Calcification”,Arch. int. Pharmacodyn.1970, pp. 269-278, vol. 186.
Doty et al., “Morphological Evidence of gap Junctions Between Bone Cells”,Calcif. Tissue Int., 1981, pp 509-512, vol. 33.
R.H. Wasserman et al., “Effect of Vitamin D3on Lanthanum Absorption: Suggestive Evidence for a Shunt Path”,Calcium Metab. Bone Metab., Bone Dis., Proc. Eur. Symp. Calcif. Tissues 10th, 1975, pp. 87-90.
International Search Report dated May 17, 2002.
Evans, C.H ,“Chapter 8:Toxicology and Pharmacology of the Lanthanides”, (1990) Biochemistry of the Lanthanides. Plenum Press, New York, NY, pp. 339-389.
Thomas J. Haley, “Pharmacology and Toxicology of the Rare Earth Elements”, Journal of Pharmaceutical Sciences, vol. 54, No. 5 (1965), pp. 663-669.
Tandra Das et al., “Effects of Lanthanum in Cellular Systems: A Review” Biological Trace Element Research, vol. 18, (1988), pp. 201-228.

Affiliated with

Also associated with

Rating

Treatment of bone diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of bone diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bone diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3531752